Log in
Hope4PMOS (Harnessing biobanking, Organ models, and Patient Empowerment for a better quality of life for women living with PMOS) is a Horizon Europe - Health project funded by the European Commission (Grant Agreement No. 101288747). Hope4PMOS is a 48-month project with a total budget and EU contribution of 6M€ that started on 1 June 2026 and runs through 31 May 2030. The project focuses on Polyendocrine Metabolic Ovary Syndrome (PMOS), a complex condition affecting 7–12% of women of reproductive age that remains under-researched and frequently suffers from diagnostic delays.
The hope4PMOS project aims to transform PMOS research, diagnosis, disease management, and therapeutic innovation through cutting-edge science and patient-centered solutions. To overcome the limitations of inadequate animal models, the project will develop advanced human 3D organ models of key systems involved in PMOS, including the neuroendocrine axis, adipose tissue, and reproductive organs. These models will be powered by a standardized multi-organ European biobanking protocol combining minimally invasive sampling with innovative techniques. Additionally, hope4PMOS will co-create a digital health platform to empower patients, guide them toward diagnosis, and analyze self-reported data to discover digital biomarkers, ultimately advancing pathological insight and accelerating personalized medicine for PMOS.
Omniscope is contributing its high-precision immune-profiling technology to help unlock the mysteries of PMOS. Women with PMOS often face long delays before receiving an accurate diagnosis, largely because traditional research tools struggle to capture the full complexity of the disease. Omniscope is working to change that by diving deep into the immune system, examining blood and tissue samples from patients and comparing them to healthy controls.Using osTCR, Omniscope's proprietary sequencing technology that offers 100 times the resolution of standard methods, the team will analyze individual immune cells to identify subtle patterns of chronic inflammation that were previously invisible. By combining these high-resolution immune profiles with clinical parameters (such as age, BMI, and hormone levels) using machine learning and AI frameworks, Omniscope aims to build a comprehensive immune cell atlas across blood, ovarian, and endometrial tissues. This work will uncover unique inflammatory signatures to enable earlier, more accurate diagnoses and support predictive frameworks for patient stratification and targeted therapies. Through this work, Omniscope is helping turn complex biological data into real-world progress for women living with PMOS.
BAXERNA 2.0 will establish a new vaccine development pipeline based on dramatically improved immunopeptidomics screening and innovative mRNA vaccine formulation. We will use our powerful new pipeline to develop novel mRNA vaccines against three bacterial pathogens that can persist within phagocytic cells: Mycobacterium tuberculosis (MTB), Mycobacterium ulcerans (MU), and Acinetobacter baumannii (AB). MTB and AB are clinically problematic bacteria with alarming levels of antimicrobial resistance (AMR), while MU is an important neglected tropical disease.
Although vaccines are recognized as highly effective tools to mitigate AMR and tropical diseases, effective vaccine development for these (facultative) intracellular bacteria is held back by a lack of known antigens, and by current vaccine platforms struggling to elicit the required strong cellular immune responses. We will overcome both limitations here through two key innovations: (i) novel proteomics and proteomics informatics approaches for immunopeptidomics to allow highly sensitive discovery and prioritization of bacterial epitopes presented on infected cells; and (ii) novel mRNA vaccines to induce both humoral and cellular immune responses, with innovative adjuvants to strengthen adaptive immunity, and to modulate innate immunity. Vaccine production will be done according to GMP standards, and we will pursue novel, low-cost production methods to enable local production and much-needed improved vaccine stability.We will characterize innate and adaptive immune responses in detail in human cellular models and mouse infection models.
In addition, top vaccine candidates for MTB will be evaluated in unique primate models, followed by testing of the lead candidate in a first-in-human Phase I clinical trial.Together, we will establish our novel vaccine development pipeline as a blueprint for world-leading, next-generation bacterial vaccine development.
Omniscope Limited is involved in Work Package 5 (WP5) and Work Package 6 (WP6) of the BAXERNA 2.0 project. In WP5, Omniscope will expand its osT platform and analysis capacity to non-human primate (NHP) models, performing deep single-cell T cell receptor (TCR) sequencing on pre/post-vaccination peripheral blood samples to characterize cellular adaptive immune responses and refine xeno-epitope mRNA vaccines. For WP6, Omniscope will apply its osT sequencing technology to analyze TCR sequences from peripheral blood samples collected before and after MTB vaccination in human clinical trial subjects, providing a detailed assessment of adaptive immune system behavior and aiding in the fine-tuning of vaccine designs. Omniscope's unique capability to profile up to 1,000,000 T cells at single-cell resolution offers unprecedented depth and accuracy for quantifying adaptive immunity dynamics during infection or vaccination. This involvement significantly strengthens BAXERNA 2.0's ability to gain insights into cellular immune responses and supports the overall goal of establishing a novel vaccine development pipeline.
This project, called EPIVINF, is a Horizon Europe - Health project, funded by the European Commission. EPIVINF is a 60-month project with a total budget of EUR 6.9 million and started on the 1st of September 2022. The budget allocated to Omniscope is EUR 1.5 million.
The EPIVINF project aims to study the epigenetic regulation of host factors critical for immune control and neurological health during acute viral infections. HIV and SARS-CoV-2 will be studied due to their shared features and impact on millions of people. The project hypothesizes that understanding epigenetic profiles, immune responses, and epigenetic control mechanisms in these infections will provide insights into how different individuals react and how different infections share similar mechanisms.
The project will use cutting-edge epigenetic analyses, immune monitoring tools, disease-relevant animal models, and samples from unique human vaccine trials to gain a deep understanding of viral infections' impact on the immune phenotype, potentially leading to novel therapeutic interventions. Patient follow-up will be extensive, identifying factors predisposing to different clinical symptoms and disease progression.
Omniscope is a partner in all work packages and leads work pack 3, focusing on the epigenetic regulation of the response to HIV and SARS-CoV-2 vaccination. Omniscope will conduct single-cell transcriptomics analyses in isolated T and B cell populations from infected individuals, and work on the BCR and TCR repertoire evolution upon vaccination. Further Omniscope will provide insights into the optimal timing for immune receptor analyses and will contribute to work pack 5 by providing cleaned and curated 10X transcriptomics data, and TCR / BCR repertoire data for suitable database development. The project aims to generate extensive data on viral infections and identify relevant epigenetic biomarkers to improve therapeutic interventions.
Hope4PMOS (Harnessing biobanking, Organ models, and Patient Empowerment for a better quality of life for women living with PMOS) is a Horizon Europe - Health project funded by the European Commission (Grant Agreement No. 101288747). Hope4PMOS is a 48-month project with a total budget and EU contribution of 6M€ that started on 1 June 2026 and runs through 31 May 2030. The project focuses on Polyendocrine Metabolic Ovary Syndrome (PMOS), a complex condition affecting 7–12% of women of reproductive age that remains under-researched and frequently suffers from diagnostic delays.
The hope4PMOS project aims to transform PMOS research, diagnosis, disease management, and therapeutic innovation through cutting-edge science and patient-centered solutions. To overcome the limitations of inadequate animal models, the project will develop advanced human 3D organ models of key systems involved in PMOS, including the neuroendocrine axis, adipose tissue, and reproductive organs. These models will be powered by a standardized multi-organ European biobanking protocol combining minimally invasive sampling with innovative techniques. Additionally, hope4PMOS will co-create a digital health platform to empower patients, guide them toward diagnosis, and analyze self-reported data to discover digital biomarkers, ultimately advancing pathological insight and accelerating personalized medicine for PMOS.
Omniscope is contributing its high-precision immune-profiling technology to help unlock the mysteries of PMOS. Women with PMOS often face long delays before receiving an accurate diagnosis, largely because traditional research tools struggle to capture the full complexity of the disease. Omniscope is working to change that by diving deep into the immune system, examining blood and tissue samples from patients and comparing them to healthy controls.Using osTCR, Omniscope's proprietary sequencing technology that offers 100 times the resolution of standard methods, the team will analyze individual immune cells to identify subtle patterns of chronic inflammation that were previously invisible. By combining these high-resolution immune profiles with clinical parameters (such as age, BMI, and hormone levels) using machine learning and AI frameworks, Omniscope aims to build a comprehensive immune cell atlas across blood, ovarian, and endometrial tissues. This work will uncover unique inflammatory signatures to enable earlier, more accurate diagnoses and support predictive frameworks for patient stratification and targeted therapies. Through this work, Omniscope is helping turn complex biological data into real-world progress for women living with PMOS.
Patient survival after lung transplantation (LTx) for end-stage pulmonary disease is poor (5-year survival rate of 59%) due to ischemia reperfusion injury (IRI) and graft rejection. No therapies are available to prevent IRI, and current immunosuppression causes toxicity and morbidity. Novel strategies are required that can mask the graft from the recipient’s immune system The LifeLUNG initiative unites the critical building blocks available in Europe to advance towards a novel paradigm for LTx. Ex vivo lung perfusion (EVLP) is a clinically used platform to maintain active lung physiology outside the body, making pre-LTx organ engineering a reality. The project aims to advancing EVLP technology to enhance our understanding of transplant rejection through accessible models. By utilizing biobanks of lung biopsies from both clinical LTx cases and established animal models of IRI and rejection, LifeLUNG will apply advanced machine learning and AI-driven deep sequencing to identify key immune factors and gene targets. The latter will be targeted in LifeLUNG with gene therapeutic agents (GTAs) that can be delivered during EVLP to selectively modulate immune responses. Several delivery tools including adeno-associated viral vectors, virus-like particles and lipid nanoparticles, will be tailored to ensure precise and graft-specific gene modulation, enhancing the therapeutic potential for reducing IRI and preventing rejection. Also the efficient production strategies of these GTAs will be an integral part of LifeLUNG. In parallel, LifeLUNG will explore the economic and ethical paradigms of genetic modification of lung transplantation and reflect its implementation into the broader research and clinical framework. The interdisciplinary nature of LifeLUNG will support the training of 15 doctoral candidates across clinical, academic, and industrial sectors, fostering collaboration and the development of transferable skills to advance the research objectives.
Omniscope is hosting one doctoral candidate, DC-6, whose project is titled "Charting host immunity against lung organ transplants." This project aims to develop a single-cell atlas of immune cells in dysfunctional and rejected lungs, characterize the immune mechanisms underlying PGD and chronic rejection, identify T cells and genes for drug design and gene therapy, and build computational models for predicting PGD and chronic rejection risk. The ultimate goal is to provide a foundation for targeted therapeutic interventions and precision medicine tools for managing lung transplant outcomes. Beyond hosting DC-6, Omniscope plays a significant role as an industrial partner in the LifeLUNG project. Omniscope is involved in research, specifically leading Work Package 2, "Omics & AI," where we contribute expertise in advanced multi-omics technologies and proprietary TCR sequencing. Omniscope also participates in the training program, offering workshops on "Effective Team Collaboration & Management," and is actively involved in the recruitment and supervision of doctoral candidates. Furthermore, Omniscope is a member of the Impact Committee, working to assess the project's impact and develop strategies for exploitation and dissemination, with a focus on commercializing the Immune Atlas database and data from DC-6's project to stratify asthma and COPD patients and enhance the company's market position.
Asthma and COPD are prevalent, chronic respiratory diseases, with high incidence and societal costs. Current treatment is based on a ’one-size-fits-all’ approach, that suppresses symptoms, but fails to achieve stable remission of disease. There is an urgent need to replace these generic treatments with precision medicine for asthma and COPD. This transition is hampered by the complexity of asthma and COPD on the one hand, and by the lack of an integrated, multidisciplinary approach to achieve progress towards precision medicine for these chronic respiratory disorders on the other hand. The complexity of asthma and COPD is caused by multiple molecular mechanisms that independently contribute to the pathogenesis of disease. Their activity varies over time, and between patients, leading to substantial heterogeneity of asthma and COPD: identical clinical phenotypes can be caused by dissimilar molecular and cellular mechanisms, and requiring different treatments.
The vision of RESPIRE-EXCEL is to achieve the transition to precision medicine in asthma and COPD by cross-sectoral and multi-disciplinary collaboration in respiratory research, drug discovery and development. The success of this approach depends on respiratory scientists with the competence to combine expertise across disciplines, and the skills to collaborate with experts from industry, healthcare and academia. Therefore, the goal of RESPIRE-EXCEL is to enable the transition to precision medicine for asthma and COPD by training the next generation of translational and physician scientists with the skills, cross-sectoral competences andmultidisciplinary knowledge to identify the molecular mechanisms of asthma and COPD, develop improved prognostic and diagnostic biomarkers to detect their activity in individual patients, and support the development of novel treatments that target individual diseasemechanisms, aiming to achieve stable remission of disease in asthma and COPD through precision medicine.
Omniscope is a key industrial partner in the RESPIRE-EXCEL project, contributing to one doctoral candidate (DC-7) project. DC-7's project focuses on creating an inflammation atlas of circulating immune cells to identify asthma and COPD biomarkers. This involves tracking Adaptive Immune Receptor Repertoire (AIRR) signatures of T and B cells to build a PBMC-based classifier for patient subgroups, aiding in precision medicine. Omniscope leads Deliverable D3.6 ("AIRR in asthma and COPD") and are involved in WP3 (identifying biomarkers for asthma and COPD). Omniscope also supports training through a Cross-Sectoral Workshop on team collaboration, provides supervision for DC-7, sits on the Impact Committee, and participates in project governance through the Supervisory Board. This involvement aims to enhance Omniscope's competitiveness and open new market potential in precision medicine for respiratory diseases.
This project, called SIGNATURE, is part of the Marie Skłodowska-Curie Actions Programme and the Horizon Europe program, the European Union's R&D&I plan. SIGNATURE is a 48-month project with a budget of EUR 2.6 Million, starting in 2023. Its network will train enterprising, innovative, and resilient doctoral students, capable of facing current and future challenges and turning knowledge and ideas into products and services for economic and social benefit.
Autoimmune disorders are highlyImmune-mediated disorders and highly heterogeneous entities for which the mechanisms of disease progression and therapeutic responses are only recently beginning to be understood. The patterns of transcriptome are the reflection of distinct cell types that are involved in the development of the disease process.
The project is based on a unique ongoing platform of clinical groups across Europe and specialists in cell and molecular profiling, imaging analyses, single cell sequencing and analysis. It will have the availability to existing clinical studies and clinical trials, as well as prospective studies of which new data will be produced.
Further a specialized training program will be developed where students will be able to visualize the overall work from design to analysis of the data, and will engage in the unique multi-disciplinariry of this platform.
Omniscope is one of the associated partners to SIGNATURE and will be involved in delivering a 10-day course (2 ECTS) on single-cell data generation and analysis, and a 1-day workshop about founding a biotech company (0.5 ECTS).
While endemic to the tropics, flaviviruses like Zika, dengue, West Nile or yellow fever virus are re-emerging pathogens of global health concern. Climate change and urbanization have largely contributed to the dissemination of their mosquito vector and Europe has in recent years been regularly confronted with autochthonous cases. Few vaccines are licensed to prevent flavivirus disease, but the yellow fever 17D (YF17D) vaccine has a unique track record of efficiency and safety.Intriguingly, despite its success, how YF17D induces immunity remains poorly understood. The YELLOW4FLAVI consortium aims to fill the gaps in our understanding of the mechanism of action of this vaccine by linking the structure of the viral particle to the resulting host immune response, in order to learn about optimal vaccine design for flaviviruses in general. Since social acceptance of vaccines is critical for their success, we will also develop optimal communication methods. This will provide us with the tools to tailor vaccine design not only to achieve optimal immune protection, but also to facilitate actual implementation.
We are molecular and structural virologists, cell biologists, immunologists, computational scientists, clinicians, and social scientists assembled in a tight collaborative network. To pursue our goal of obtaining a blueprint for determinants of long-lasting immunity for flavivirus vaccine candidates, we will use cutting-edge technologies like cryo-EM, super resolution microscopy, spatial transcriptomics, high-dimensional spectral flowcytometry, single-cell RNA sequencing, advanced cell engineering, small animal models, and clinical studies. In a unique manner, the consortium thereby follows a thread of events from the early response at the site of vaccine injection to the population perception of vaccination, harnessing an enhanced understanding of one of the most successful vaccines of mankind for the development of novel lines of defense against new and old threats.
Omniscope Limited is involved in Work Package 3 (WP3), Work Package 6 (WP6), and Work Package 7 (WP7) of the Yellow4FLAVI project. In WP3, Omniscope leads Task 3.5, focusing on Deep Immune Repertoire Analysis to Correlate Protective Immunity, utilizing their osT/B (single-cell) and osTCR/BCR (single-molecule) sequencing technologies to generate an expanded dataset from vaccination samples and study T cell responses in hamster and NHP models. This involves analyzing human clinical cohort samples, NHP samples, and hamster samples, with the goal of identifying immunodominant epitopes and tracing the chain of events driving protective immune responses. Omniscope's advanced sequencing capabilities will provide high-resolution data crucial for refining vaccine designs and improving immune response predictions.
